El real decreto de medicamentos en situaciones especiales y la farmacotecnia hospitalaria

Salom, Pedro García; Herreros, José María Alonso

doi:10.1016/j.farma.2010.02.001

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En el artículo "El real decreto de medicamentos en situaciones especiales y la farmacotecnia hospitalaria" (García & Alonso, 2010), los autores describen cómo a partir de la emisión del Decreto 1015/2009, el Estado Español proporciona una amplia cobertura legal a los medicamentos no legislados hasta ese momento, además, manifiestan la responsabilidad a la que se enfrentan los médicos tratantes al sobrellevar la responsabilidad absoluta frente a la prescripción y utilización de los medicamentos (García & Alonso, 2010).…”

Section: )unclassified

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks

Abraham

Spooner

2014

Clinical Infectious Diseases

View full text Add to dashboard Cite

The existing standard of care for chronic hepatitis C virus (HCV) infection includes the use of pegylated interferon and ribavirin as primary components of treatment, with the addition of a direct-acting antiviral for genotype 1 infection. Sofosbuvir, an oral nucleotide inhibitor of the HCV nonstructural protein 5B RNA-dependent RNA polymerase enzyme, was recently approved for use in combination with ribavirin and/or pegylated interferon for chronic HCV infection, depending on the genotype. Sofosbuvir is orally administered, and peak plasma concentrations are not affected by food. The drug is renally eliminated and does not require adjustment in mild to moderate renal insufficiency or in any degree of hepatic impairment. Sofosbuvir is not metabolized by cytochrome P450 isoenzymes, nor does it induce or inhibit the metabolism of agents that are substrates of these enzymes. Sofosbuvir demonstrates a high barrier to resistance and was well tolerated by patients in clinical trials. Overall efficacy rates vary between 70% and 90%.

show abstract

Section: )unclassified

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks

Abraham

Spooner

2014

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

El real decreto de medicamentos en situaciones especiales y la farmacotecnia hospitalaria

Cited by 1 publication

References 4 publications

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks

Contact Info

Product

Resources

About